$VIRX
Viracta Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018020104 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.820M $3.670M
YoY Change -23.16% -8.25%
% of Gross Profit
Research & Development $3.760M $4.940M
YoY Change -23.89% -25.26%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $6.582M $8.612M
YoY Change -23.57% -18.75%
Operating Profit -$6.582M -$8.612M
YoY Change -23.57%
Interest Expense $287.0K $344.0K
YoY Change -16.57% -171.67%
% of Operating Profit
Other Income/Expense, Net $29.00K $114.0K
YoY Change -74.56% 470.0%
Pretax Income -$6.840M -$8.840M
YoY Change -22.62% -15.41%
Income Tax
% Of Pretax Income
Net Earnings -$6.840M -$8.842M
YoY Change -22.64% -15.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.41
Diluted Earnings Per Share -$6.980M -$0.41
COMMON SHARES
Basic Shares Outstanding 21.52M
Diluted Shares Outstanding 21.52M

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.40M $22.70M
YoY Change -10.13% -31.42%
Cash & Equivalents $17.03M $11.67M
Short-Term Investments $3.400M $11.00M
Other Short-Term Assets $1.500M $800.0K
YoY Change 87.5% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.90M $23.50M
YoY Change -6.81% -30.88%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $1.400M
YoY Change -92.86%
Total Long-Term Assets $100.0K $1.400M
YoY Change -92.86%
TOTAL ASSETS
Total Short-Term Assets $21.90M $23.50M
Total Long-Term Assets $100.0K $1.400M
Total Assets $22.00M $24.90M
YoY Change -11.65% -26.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.600M $2.300M
YoY Change -30.43% -17.86%
Accrued Expenses $3.200M $3.000M
YoY Change 6.67% -40.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.300M $1.700M
YoY Change 329.41% 112.5%
Total Short-Term Liabilities $12.00M $7.000M
YoY Change 71.43% -32.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $5.400M
YoY Change -100.0% -59.7%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $5.400M
YoY Change -100.0% -60.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.00M $7.000M
Total Long-Term Liabilities $0.00 $5.400M
Total Liabilities $12.00M $12.40M
YoY Change -3.23% -48.12%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.975M $12.50M
YoY Change
Total Liabilities & Shareholders Equity $22.00M $24.90M
YoY Change -11.65% -26.76%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$6.840M -$8.842M
YoY Change -22.64% -15.39%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$5.900M -$10.81M
YoY Change -45.42% 14.76%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $640.0K $12.70M
YoY Change -94.96% -268.88%
Cash From Investing Activities $640.0K $12.68M
YoY Change -94.95% -268.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 920.0K -1.670M
YoY Change -155.09% -166.01%
NET CHANGE
Cash From Operating Activities -5.900M -10.81M
Cash From Investing Activities 640.0K 12.68M
Cash From Financing Activities 920.0K -1.670M
Net Change In Cash -4.340M 200.0K
YoY Change -2270.0% -101.39%
FREE CASH FLOW
Cash From Operating Activities -$5.900M -$10.81M
Capital Expenditures $0.00 -$30.00K
Free Cash Flow -$5.900M -$10.78M
YoY Change -45.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
112000
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
635973000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
633436000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6183000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7613000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
6582000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
8612000
us-gaap Operating Expenses
OperatingExpenses
13910000
us-gaap Operating Expenses
OperatingExpenses
18716000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6582000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8612000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13673000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18047000
CY2018Q2 us-gaap Interest Expense
InterestExpense
287000
CY2017Q2 us-gaap Interest Expense
InterestExpense
344000
us-gaap Interest Expense
InterestExpense
568000
us-gaap Interest Expense
InterestExpense
828000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
114000
CY2018Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12576000
CY2018Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
12576000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
128000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
199000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6840000
CY2018Q2 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
3398000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-8842000
us-gaap Net Income Loss
NetIncomeLoss
-14113000
us-gaap Net Income Loss
NetIncomeLoss
-18676000
CY2018Q2 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
4000
CY2017Q2 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
9000
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
6000
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
13000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6836000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8833000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14107000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18663000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34417000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21521000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34381000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21276000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
us-gaap Share Based Compensation
ShareBasedCompensation
1548000
us-gaap Share Based Compensation
ShareBasedCompensation
1923000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
96000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
156000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-984000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1568000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-144000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
406000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-215000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-625000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-485000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-828000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-121000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-648000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-610000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12446000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20466000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1382000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
23534000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1382000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23508000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7615000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
851000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
8056000
snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
264000
snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
133000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1115000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
574000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9949000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3616000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8056000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11672000
us-gaap Stock Issued1
StockIssued1
448000
snss Legal Expenses Accrued As Cost Of Equity Financing
LegalExpensesAccruedAsCostOfEquityFinancing
-125000
CY2018Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
15974000
CY2018Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s condensed consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, debt instruments, revenue recognition, stock-based compensation and clinical trial accounting. </p></div>
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
20400000
snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15097000
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7117000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
25243000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
20470000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20470000
CY2018Q2 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
1000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
25250000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2017Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
4780000
CY2017Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
7000
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
3397000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
7000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
4773000
CY2018Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018Q2 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675
snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2018Q2 us-gaap Notes Payable
NotesPayable
7500000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1036000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1548000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1923000

Files In Submission

Name View Source Status
0001564590-18-020104-index-headers.html Edgar Link pending
0001564590-18-020104-index.html Edgar Link pending
0001564590-18-020104.txt Edgar Link pending
0001564590-18-020104-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g5cowojnbrsc000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20180630.htm Edgar Link pending
snss-20180630.xml Edgar Link completed
snss-20180630.xsd Edgar Link pending
snss-20180630_cal.xml Edgar Link unprocessable
snss-20180630_def.xml Edgar Link unprocessable
snss-20180630_lab.xml Edgar Link unprocessable
snss-20180630_pre.xml Edgar Link unprocessable
snss-ex311_75.htm Edgar Link pending
snss-ex311_8.htm Edgar Link pending
snss-ex312_7.htm Edgar Link pending
snss-ex321_6.htm Edgar Link pending